Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PYGB | P11216 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791244 | 0.88 | MAPK1 (0.79) | MAPK1ALDH1A1THRBNOD2SMN1; SMN2 | |
| SCHEMBL20235169 | 0.84 | MAPK1 (0.49) | MAPK1ALDH1A1THRBNOD2SMN1; SMN2 | |
| SCHEMBL18102361 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL22311649 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL9914082 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL18708293 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL22311199 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL22311210 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL14025370 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 | |
| SCHEMBL11946954 | 0.84 | ALDH1A1 (0.63) | MAPK1ALDH1A1THRBSMN1; SMN2CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | MAPK1 1393/4885ALDH1A1 797/4885THRB 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.